# AZUR-1 (NCT05723562)

> A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05723562
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: GlaxoSmithKline
- Conditions: Neoplasms, Rectal
- Interventions: Dostarlimab
- Enrollment: 154
- Primary outcome: Number of Participants with Sustained Complete Clinical Response for 12 Months (cCR12) as assessed by Independent Central Review (ICR)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 18
- YouTube: 8

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=azur-1-nct05723562

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05723562", "email": "<work email>"}; the inbox owner confirms by the emailed link.